Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012	Nov. 05, 2012	Dec. 31, 2011
Document And Entity Information
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	0000025743
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	99,784,982	99,784,982	82,978,804
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2012

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Consolidated Balance Sheets
Cash	$ 154,247	$ 126,421
Accounts receivable, net of allowance for doubtful accounts of $34,713 and $1,500, respectively	270,262	26,720
Inventory	955,129	588,073
Other current assets	851,839	496,060
Total current assets	2,231,477	1,237,274
Property and equipment, net	95,066	70,113
Other Assets:
Prepaid Expenses	1,048,952	80,515
Patent costs	107,094	18,870
Security deposit	31,949	31,949
Total other assets	1,187,995	131,334
Total assets	3,514,538	1,438,721
Accounts payable	1,031,053	306,511
Deferred Revenue	701,929
Notes payable	2,099,220	2,150,000
Notes payable, related parties	150,000	200,000
Accrued interest	16,986	28,321
Other current liabilities	428,378	465,747
Total current liabilities	4,427,566	3,150,579
Long-Term Liabilities:
Notes payable, net of debt discount of $1,350,162 and $0, respectively	3,341,686
Accrued Interest	79,111
Total Long-term liabilities	3,420,797
Total liabilities	7,848,363	3,150,579
Commitments and Contingencies
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 250,000,000 shares authorized; 99,784,982 and 82,978,804 issued and outstanding, respectively	99,785	82,979
Additional paid in capital	50,310,369	15,198,241
Subscriptions receivable	(8,358,001)
Accumulated deficit	(46,385,978)	(16,993,078)
Total stockholder' deficit	(4,333,825)	(1,711,858)
Total liabilities and stockholders' deficit	$ 3,514,538	$ 1,438,721

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Consolidated Balance Sheets Parenthetical
Allowance for doubtful accounts	$ 34,713	$ 1,500
Debt discount on notes payable	$ 1,350,162	$ 0
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	99,784,982	82,978,804
Common stock, shares outstanding	99,784,982	82,978,804

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Condensed Consolidated Statements Of Operations
Revenues, net	$ 1,036,456	$ 539,572	$ 2,577,298	$ 1,533,731
Cost of goods sold	306,843	241,688	1,015,337	684,420
Gross profit	729,613	297,884	1,561,961	849,311
Operating expenses:
Sales, general, and administration	3,291,357	1,633,180	9,691,892	3,818,710
Research and development	1,334,005	95,223	2,579,308	255,953
Depreciation and amortization	14,839	13,711	43,952	41,133
Total operating expense	4,640,201	1,742,114	12,315,152	4,115,796
Operating loss	(3,910,588)	(1,444,230)	(10,753,191)	(3,266,485)
Other income and (expense)
Miscellaneous Income	932	75	2,486	75
Loss on extinguishment of debt	(197,383)		(10,505,247)
Beneficial Conversion Feature			(6,716,504)
Amortization of debt discount	(50,099)	(14,360)	(1,159,375)	(17,950)
Interest expense	(84,376)	(16,505)	(225,834)	(16,737)
Loan guaranty costs	(11,745)	(11,745)	(35,235)	(26,414)
Total other income (expense)	(342,671)	(42,535)	(18,639,709)	(61,026)
Loss before taxes	(4,253,259)	(1,486,765)	(29,392,900)	(3,327,511)
Provision for income taxes
Net loss	$ (4,253,259)	$ (1,486,765)	$ (29,392,900)	$ (3,327,511)
Loss per share, basic and diluted:
Net loss per share, basic and diluted	$ (0.04)	$ (0.03)	$ (0.33)	$ (0.06)
Weighted average number of shares outstanding	95,895,677	58,407,327	88,892,757	57,275,797

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES - CONTINUING OPERATIONS
Net loss	$ (29,392,900)	$ (3,327,511)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	43,952	41,133
Provision for doubtful accounts	33,213
Loss on debt extinguishment	10,505,247
Beneficial Conversion Feature	6,716,504
Amortization of debt discount	1,159,375	17,950
Stock based compensation	1,031,685	152,824
Stock based expense for services	233,093
Loan guaranty costs	35,235	26,414
Changes in assets and liabilities
Accounts receivable	(276,755)	(20,492)
Inventory	(367,056)	(207,179)
Other current assets	302,777	(1,085)
Accounts payable	724,542	138,449
Accrued interest	216,281	872
Deferred Revenue	701,929
Accrued expenses and other current liabilities	(66,087)	96,636
Net cash flows used in operating activities	(8,399,000)	(3,081,989)
CASH FLOWS FROM INVESTING ACTIVITIES
Vendor deposits	(331,702)	(10,081)
Purchase of property and equipment	(68,904)	(28,766)
Patent costs, net of abandoned costs	(88,223)
Net cash flows used in investing activities	(488,829)	(38,847)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes and loans payable	8,700,000	1,996,023
Proceeds from exercise of options	190,999
Proceeds from sale of common stock	125,001
Proceeds from sale of warrants	400
Proceeds from sale of membership units		707,000
Proceeds from notes payable - related parties		151,596
Repayment of notes payable	(50,780)	(2,778)
Repayment of notes payable - related party	(50,000)
Net cash flows provided by financing activities	8,915,620	2,851,841
Increase (decrease) in cash	27,826	(268,995)
Cash, beginning of period	126,421	422,939
Cash, end of period	154,247	153,944
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	37,087
Cash paid for income taxes
Warrants exercised in exchange for debt and accrued interest	3,102,000
Warrants issued for financing	2,509,537
Warrants issued for services	1,532,228
Shares issued in exchange for debt and accrued interest	1,054,658
Notes payable issued for accrued interest	$ 15,123

THE COMPANY

9 Months Ended

Sep. 30, 2012

Company

THE COMPANY

NOTE 1 – THE COMPANY

Nature of Operations

TherapeuticsMD, Inc. ("Therapeutics” or the “Company”) has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company incorporated on May 13, 2008 ("VitaMed”) and BocaGreenMD, Inc., a Nevada corporation, incorporated on January 10, 2012 ("BocaGreen”).

Therapeutics is a specialty pharmaceutical company focused on creating safe and effective therapies exclusively for women, including (i) prenatal and women’s multi-vitamins, (ii) iron, calcium and vitamin D supplements, (iii) natural (non-hormonal) menopause relief and (iv) scar reduction creams. The Company also has three hormone replacement therapy ("HRT”) drug candidates that have received Investigational New Drug Application ("IND”) acceptance by the U.S. Food and Drug Administration ("FDA”). The current product lines of the Company are sold through VitaMed and BocaGreen. We have a national sales force that calls on physicians and pharmacies and markets prescription prenatal vitamins, over-the-counter ("OTC”) nutritional supplements and other medical products through pharmacies and our website with the recommendation of physicians by creating a unique value proposition for patients, physician/providers and insurance payors. Our primary objective is to be the sole prenatal vitamin brand recommended by physicians to all their patients by becoming the new standard in prenatal vitamins with a complete line of personal products all under one quality brand.

New Products

The Company filed three Investigational New Drug applications ("INDs”) in 2012, all of which have been accepted by the FDA for hormone therapy. These drugs are known as TX12001HR, a combined progestin and estrogen drug candidate, TX12002HR, a progestin only drug candidate and TX12003HR, an estrogen only drug candidate. Since these INDs have been accepted by the FDA, Phase I and III clinical trials may be commenced. The Company anticipates beginning these trials in the near future. Upon completion, the Company may seek FDA approval for these drug candidates.

On November 6, 2012, the Company released three products in its BocaGreen generic prescription line, namely: BocaGreenMD™ Prena1, BocaGreenMD™ Prena1 Plus, and BocaGreenMD™ Prena1 Chew.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended September 30, 2012, the Company incurred a loss from operations of approximately $10,753,000, had negative cash flows from operations of approximately $8,399,000 and had an accumulated deficit of approximately $46,386,000. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include raising additional proceeds from debt and equity transactions and to continue to increase its sales and marketing activities, however, there are no assurances that management will be successful in their efforts. The financial statements do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2012
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 – SUBSEQUENT EVENTS Private Placement On September 26, 2012, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with multiple investors (collectively, the “Investors”) relating to the issuance and sale of the Company’s Common Stock in a private placement. The Purchase Agreement was closed on October 2, 2012 (the “Closing Date”) through which the Company sold an aggregate of 3,953,489 shares of its Common Stock (the “Shares”) at $2.15 per share for an aggregate purchase price of $8,500,001. The Company plans to use the net proceeds from the sale of the Shares for research and development of the Company’s drug candidates, working capital and general corporate purposes. In connection with the private placement, Jefferies & Company, Inc. ("Jefferies”) served as the Company’s exclusive placement agent. Jefferies’ compensation for the transaction is a cash fee of $552,500. The Company also paid legal fees and expenses for the Investors in the aggregate of $27,000, resulting in net proceeds to the Company of $7,920,501. The Shares were issued in reliance upon the exemptions from registration under the Securities Act of 1933, as amended, provided by Section 4(2) and Rule 506 of Regulation D promulgated thereunder. The Shares were issued directly by the Company and did not involve a public offering or general solicitation. The Investors in the private placement are “Accredited Investors” as that term is defined in Rule 501 of Regulation D and are acquiring the Shares for investment only and not with a present view toward, or for resale in connection with, the public sale or distribution thereof. As part of the Purchase Agreement, the Company agreed to file a registration statement (the “Registration Statement”) covering the resale of the Shares no later than 45 days from the Closing Date. The Company shall use its best efforts to effect the registration (including a declaration of effectiveness of the Registration Statement by the SEC) no later than 90 days from the Closing Date (120 days if reviewed by SEC) (the “Effectiveness Date”). If the Registration Statement does not become effective on or before the Effectiveness Date, the Company has agreed, among other things, to pay to the Investors 1.5% of each Investor’s aggregate purchase price of the Shares for each 30-day period that the Registration Statement is not effective, up to a maximum of 10% of such aggregate purchase price. New Products On November 6, 2012, the Company plans the release of the following new products in its BocaGreen generic prescription line: BocaGreenMD™ Prena1 Plus is a comprehensive single-dose dietary supplement containing one prenatal tablet with 16 vitamins and minerals, plus one softgel with 300 mg of plant-based life’s DHA. BocaGreenMD™ Prena1 is a convenient single-dose softgel with 14 vitamins, minerals and 200 mg of plant-based life’s DHA. BocaGreenMD™ Prena1 Chew is a single daily easy to chew, vanilla-flavored, chewable tablet ideal for women planning a pregnancy and those with difficulty swallowing tablets or capsules, or where nausea or morning sickness make taking tablets or capsules difficult. Employment Agreements On November 8, 2012, the Company’s Compensation Committee recommended that the Board of Directors approve employment agreements with the Company’s executive officers, namely: Chief Executive Officer (Robert G. Finizio), President (John C.K. Milligan, IV) and Chief Financial Officer (Daniel A. Cartwright) (each an “Executive; together the “Executives”). The Company’s Board of Directors approved the Employment Agreements with an effective date of November 8, 2012. With the exception of compensation, the three-year employment agreements are substantially the same with the Executives receiving employee benefits, vacation and other perquisites as may be determined from time to time and an automatic renewal option for one additional year. Conditions of termination for all employment agreements call for (i) termination immediately upon death, (ii) termination upon a disability in which the Executive is unable to perform his duties for more than 180 total calendar days during any 12-month period, (iii) voluntary termination by the Executive upon a 14 calendar day prior notice, (iv) involuntary termination by the Company without cause with 60-day notice or 90-day notice when termination is due to the non-extension of the employment term by the Company, (v) termination for cause and (vi) termination for good reason wherein the Executive shall have 90 days from the date of notice to terminate his employment. In addition, if the Company is subject to a change in control, the Executive shall be entitled to receive severance benefits as outlined therein. The employment agreements contain standard provisions for confidentiality and noncompetition. Compensation for services rendered by Robert G. Finizio as Chief Executive Officer calls for: (i) a time-based ten-year stock option (the “Time-Based Option”) granted and issued on November 30, 2012 ("Date of Grant”) to purchase 900,000 shares of the Company’s Common Stock with the exercise price equal to the closing price of the Company’s Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a performance-based ten-year stock option (the “Performance-Based Option”) in an amount to be determined, (iii) a base salary of not less than $355,100 per year and (iv) an annual short-term incentive compensation bonus of up to 35% of the base salary, at the discretion of the Company’s Board of Directors. Compensation for services rendered by John C.K. Milligan, IV as President calls for: (i) a Time-Based Option granted and issued on the Date of Grant to purchase 800,000 shares of the Company’s Common Stock with the exercise price equal to the closing price of the Company’s Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a Performance-Based Option in an amount to be determined, (iii) a base salary of not less than $288,100 per year and (iv) an annual short-term incentive compensation bonus of up to 30% of the base salary, at the discretion of the Board of Directors. Compensation for services rendered by Daniel A. Cartwright as Chief Financial Officer calls for: (i) a Time-Based Option granted and issued on the Date of Grant to purchase 700,000 shares of the Company’s Common Stock with the exercise price equal to the closing price of the Company’s Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a Performance-Based Option in an amount to be determined, (iii) a base salary of not less than $257,100 per year and (iv) an annual short-term incentive compensation bonus of up to 30% of the base salary, at the discretion of the Company’s Board of Directors.

THE COMPANY (Policies)	9 Months Ended
THE COMPANY (Policies)	Sep. 30, 2012
Company Policies
Going Concern	Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended September 30, 2012, the Company incurred a loss from operations of approximately $10,780,000 had negative cash flows from operations of approximately $8,399,000 and had an accumulated deficit of approximately $46,386,000. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include raising additional proceeds from debt and equity transactions and to continue to increase its sales and marketing activities, however, there are no assurances that management will be successful in their efforts. The financial statements do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2012
Summary Of Significant Accounting Policies Policies
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, vitaMed and BocaGreen. BocaGreen expects to begin operation during the fourth quarter 2012. All material intercompany balances and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition The Company recognizes revenue on arrangements in accordance with ASC 605, “Revenue Recognition”. Revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. Over The Counter Products The Company generates OTC revenue by sales of products primarily to retail consumers. The Company’s policy is to recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. Outbound shipping and handling fees are included in sales and are billed upon shipment. Shipping expenses are included in cost of sales. The majority of the Company’s sales are paid with credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional thirty-day money-back return policy whereby we accept product returns from our retail and eCommerce customers. The Company’s revenue from OTC sales is recognized net of returns, sales discounts, and eCommerce fees. For the nine months ended September 30, 2012 and 2011, the Company recorded an allowance for returns of $34,713 and $0, respectively. The Company estimates the allowance for returns based on historical return activity, which is reviewed, and adjusted if necessary, on a quarterly basis. Prescription Products The Company’s name brand and generic prescription products are sold primarily through drug wholesalers and retail pharmacies. The Company’s revenue from prescription product sales is recognized net of sales discounts and end-user rebates. The Company accepts returns of unsalable product from customers within a return period of six months prior to and following product expiration. The Company’s prescription products currently have a shelf-life of 24 months from date of manufacture. Given the limited history of prescriptions products, the Company currently cannot reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, the Company defers recognition of revenue on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration of the right of return. As a result of this policy, the Company has a deferred revenue balance of approximately $702,000 at September 30, 2012. The Company maintains various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The rebate program is designed to enable the end-user to return a coupon to the Company. If the coupon qualifies, the Company sends a rebate check to the end-user. The Company estimates the allowance for rebates based on industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. For the nine months ended September 30, 2012 and 2011, the Company recorded rebate expense of $19,915 and $0, respectively.
Inventories	Inventories Inventories represent packaged nutritional products and supplements which are valued at the lower of cost or market using the average cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) are record as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized.
Use of Estimates	Use of Estimates The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

THE COMPANY (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
THE COMPANY (Details Narrative) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Company Details Narrative
Operating loss	$ (3,910,588)	$ (1,444,230)	$ (10,753,191)	$ (3,266,485)
Net cash flows used in operating activities			(8,399,000)	(3,081,989)
Accumulated deficit	$ (46,385,978)		$ (46,385,978)		$ (16,993,078)

INVENTORY (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Inventory Details
Finished Product	$ 890,196	$ 588,073
Deferred Costs	64,933	0
Inventory	$ 955,129	$ 588,073

OTHER CURRENT ASSETS (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Other Current Assets Details
Prepaid consulting	$ 449,225	$ 95,962
Deposits with Vendors (Note 15)	331,702	300,503
Prepaid Insurance	40,941	52,611
Prepaid guaranty costs	20,575	46,984
Deferred offering costs	8,398	0
Other prepaid costs	998	0
Other current assets	$ 851,839	$ 496,060

FIXED ASSETS (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Fixed Assets Details
Website	$ 94,244	$ 91,743
Equipment	67,669	33,651
Furniture and fixtures	58,605	26,219
Total Fixed Assets, Gross	220,518	151,613
Accumulated depreciation	(125,452)	(81,500)
Property and equipment, net of accumulated depreciation of $43,952 and $41,133, respectively	$ 95,066	$ 70,113

FIXED ASSETS (Details Narrative) (USD $)	9 Months Ended
FIXED ASSETS (Details Narrative) (USD $)	Sep. 30, 2012	Sep. 30, 2011
Fixed Assets Details Narrative
Depreciation Expense	$ 43,952	$ 41,133

OTHER ASSETS (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Other Assets Details
Prepaid Consulting	$ 1,048,952	$ 71,689
Prepaid GuarantyCosts	0	8,826
Total Other Current Assets	$ 1,048,952	$ 80,515

OTHER CURRENT LIABILITIES (Details) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Other Current Liabilities Details
Accrued payroll and commission	$ 197,483	$ 295,915
Accrued vacation	96,124	68,438
Other accrued expenses	93,412	60,035
Dividends payable(1)	41,359	41,359
Other current liabilities	$ 428,378	$ 465,747

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Sep. 30, 2012
Other Current Liabilities Details Narrative
Dividends Payable, amount per share	$ 0.40

NOTES PAYABLE (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
NOTES PAYABLE (Details Narrative) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Promissory notes sold in January and February 2012	$ 900,000		$ 900,000
Promissory notes sold in August and September 2012	1,600,000		1,600,000
Promissory notes sold in September 2012	200,000		200,000
Promissory notes, principal	3,102,000		3,102,000
Loss on extinguishment of debt	(197,383)		(10,505,247)
Warrants exercised in exchange for debt and accrued interest			3,102,000
Warrants exercised in exchange for debt and accrued interest, number warrants			8,145,486
Amortization of debt discount	50,099	14,360	1,159,375	17,950
Notes payable, net of debt discount of $1,597,644 and $0, respectively	3,341,686		3,341,686
Debt discount on notes payable	1,350,162		1,350,162		0
Beneficial Conversion Feature			(6,716,504)
First United line of credit, maximum	300,000		300,000
First United line of credit, Personal Guarantees	100,000		100,000
First United line of credit, Personal Guarantees Warrants Issued			613,713
First United line of credit, Interest Rate	3.02%		3.02%
First United line of credit, extension Interest Rate			2.35%
First United line of credit, Outstanding Principal	299,220		299,220
Notes Term			6
Notes Paydown July 2011			200,000
Notes extension			300,000
Notes Paydown October 2011			50,000
Interest Accrued - VitaMed Promissory Notes paid in full			2,160
Promissory notes extended through October 15, 2012 - Milligan			50,000
Promissory notes extended through October 15, 2012 - BF Investments			50,000
Promissory Notes Issued December 2011			100,000
Promissory Notes Issued December 2011, value of each note			50,000
Promissory Notes Issued December 2011 outstanding balance	50,000		50,000
Interest Accrued and paid in full - Promissory Notes Issued December 2011			888
Notes payable, related parties	150,000		150,000		200,000
February 24 Debt Issuance
New Funding			1,000,000
Notes surrendered			1,700,000
Accrued Interest forfeited			15,124
Warrants Issued - Note Modification			5,685,300
Warrants Issued - new Funding			3,314,700
Fair Value of Prior Notes Extinguished			1,517,741
Debt Discount from February 24, 2012 note			197,384
Loss on extinguishment of debt			10,307,864
FV Warrants - treated as Debt Discount			859,647
Interest Expense			859,647
Additional Funding - March-May2012			2,000,000
Warrants exercised in exchange for debt and accrued interest			3,102,000
Warrants exercised in exchange for debt and accrued interest, number warrants			8,145,486
June 19 Debt Issuance
New Funding			2,000,000
Notes surrendered			2,691,847
Warrants Issued - new Funding			7,000,000
FV Warrants - treated as Debt Discount			1,649,890
Interest Rate of June 19, 2012 notes			6.00%
Amortization of debt discount	247,482		299,728
Debt discount on notes payable	1,350,162		1,350,162
February 24 and June 19 combined Debt Issuance
Amortization of debt discount	67,095		98,698
VitaMed Promissory Note
Promissory notes, principal	500,000		500,000
Warrants Issued	613,718		613,718
Interest Expense			33,204
VitaMed Senior Secured Promissory Notes Interest Rate	6.00%		6.00%
VitaMed Senior Secured Promissory Notes Issued, balance of note converted	1,054,647		1,054,647
Notes converted to shares, number of shares	2,775,415		2,775,415
Conversion Price Per share	$ 0.38		$ 0.38
Notes conversion, value	100,000		100,000
Notes conversion Common Stock	266,822		266,822
Notes conversion Common Stock price	$ 0.38		$ 0.38
First United Line of Credit
Interest Expense	1,817		6,526
December 2011 Debt Issuance
Interest Expense	1,497		6,344
Promissory Note Individual \| February 24 Debt Issuance
Interest rate on promissory notes	6.00%		6.00%
Promissory notes, principal	1,358,014		1,358,014
Warrants Issued			4,500,000
Notes surrendered			1,347,128
Promissory Note Individual \| June 19 Debt Issuance
Interest rate on promissory notes	6.00%		6.00%
Promissory notes, principal	2,347,128		2,347,128
Promissory Note Entity \| February 24 Debt Issuance
Interest rate on promissory notes	6.00%		6.00%
Promissory notes, principal	1,357,110		1,357,110
Warrants Issued			4,500,000
Notes surrendered			1,344,719
Promissory Note Entity \| June 19 Debt Issuance
Interest rate on promissory notes	6.00%		6.00%
Promissory notes, principal	$ 2,344,719		$ 2,344,719

STOCKHOLDERS' EQUITY (Details) (USD $)	9 Months Ended
STOCKHOLDERS' EQUITY (Details) (USD $)	Sep. 30, 2012
Number of Shares Under Company Warrant
Balance Beginning	3,057,627
Granted	17,332,500
Exercised	(8,145,486)
Expired	0
Cancelled	0
Balance ending	12,244,641
Vested and exercisable	11,717,927
Warrant1Member
Balance Beginning	$ 0.36
Granted	$ 1.26
Exercised	$ 0.38
Balance ending	$ 1.62
Vested and exercisable	$ 1.68
Warrant2Member
Balance Beginning	7.9
Granted	4.5
Balance ending	5.1
Vested and exercisable	4.9
Aggregate Intrinstic Value
Balance Beginning	$ 3,483,691
Granted	$ 37,957,525
Balance ending	$ 22,403,657
Vested and exercisable	$ 20,777,898

STOCKHOLDERS' EQUITY (Details 1)	9 Months Ended
STOCKHOLDERS' EQUITY (Details 1)	Sep. 30, 2012
Stockholders Equity Details 1
Risk-free interest rate, minimum	0.65%
Risk-free interest rate, maximum	2.23%
Volatility, minimum	40.77%
Volatility, maximum	44.83%
Expected life (in years)	5-6.75 years
Dividend yield	0.00%

STOCKHOLDERS' EQUITY (Details 2) (USD $)	9 Months Ended
STOCKHOLDERS' EQUITY (Details 2) (USD $)	Sep. 30, 2012
Number of Shares Under Company Option
Balance Beginning	10,590,161
Granted	2,296,750
Exercised	1,931,788
Expired	0
Cancelled	(26,428)
Balance ending	10,928,695
Vested and exercisable	7,528,886
Weighted Average Exercise Price
Balance Beginning	$ 0.16
Granted	$ 2.56
Exercised	$ 0.13
Cancelled	$ 0.24
Balance ending	$ 0.68
Vested and exercisable	$ 0.22
Weighted Average Remaining Contractual Life in Years
Balance Beginning	7 years 7 months 6 days
Granted	9 years 7 months 6 days
Balance ending	7 years 3 months 18 days
Vested and exercisable	6 years 8 months 12 days
Aggregated Intrinstic Value
Balance Beginning	$ 14,067,649
Granted	$ 2,039,838
Balance ending	30,261,370
Vested and exercisable	$ 24,349,605

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	0 Months Ended		3 Months Ended		9 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	Jul. 11, 2012	Jul. 05, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Nov. 05, 2012	Dec. 31, 2011
Common stock, shares authorized			250,000,000		250,000,000			250,000,000
Common stock, par value			$ 0.001		$ 0.001			$ 0.001
Common Stock Issued And Outstanding			99,784,982		99,784,982		99,784,982	82,978,804
Fair Value Modification Warrants Issued February 2012					$ 10,505,247
Debt discount on notes payable			1,350,162		1,350,162			0
Amortization of debt discount			50,099	14,360	1,159,375	17,950
Unamortized costs associated with Warrants			1,498,000		1,498,000
Shares authorized under LTIP plan			25,000,000		25,000,000
Shares authorized under SOP plan			10,000,000		10,000,000
Options exercised	30,685				1,630,022
Aggregate Purchase Price	14,260				166,000
Options to Employees					480,000
Options to employees exercise price	$ 0.407355	$ 0.18738			$ 2.40
Employee options vesting over four years			405,000		405,000
Employee options vesting over two years			60,000		60,000
Employee options vesting over twelve months			15,000		15,000
Noncash options exercised		21,338			245,485
Noncash options exercised aggregate purchase price					60,000
Noncash options exercised shares forfeited in lieu of cash		1,428			25,000
Noncash options exercised net options received		19,910			220,485
Weighted Average Issue Date Fair Value of Options Issued					$ 1.09
Share based compensation expense					1,004,472	166,233
Total Unrecognized Estimated Compensation Expense			1,730,000		1,730,000
Weighted Average Remaining Term			1.7		1.7
Warrants Issued in March 2012
Warrants issued for consulting services					31,000
Warrants issued for consulting services, Term					5
Warrants issued for consulting services, Volatility					44.81%
Warrants issued for consulting services, Risk Free Rate					1.04%
Warrants issued for consulting services, Dividend Yield					0.00%
Warrants issued for consulting services, Consulting Expense recognized					29,736
Warrants Issued in May 2012
Warrants issued for consulting services					1,300,000
Warrants issued for consulting services, Term					5
Warrants issued for consulting services, Volatility					44.71%
Warrants issued for consulting services, Risk Free Rate					0.74%
Warrants issued for consulting services, Dividend Yield					0.00%
FV of Warrants issued for consulting services					1,532,228
Warrants issued for consulting services, Prepaid Consulting Expense Short Term					306,446
Warrants issued for consulting services, Prepaid Consulting Expense Long Term					1,043,787
Warrants issued for consulting services, Consulting Expense recognized			90,132		127,913
Warrants Issued in June 2012
Warrants issued for consulting services					1,500
Warrants issued for consulting services, Term					5
Warrants issued for consulting services, Volatility					44.78%
Warrants issued for consulting services, Risk Free Rate					0.72%
Warrants issued for consulting services, Dividend Yield					0.00%
Warrants issued for consulting services, Consulting Expense recognized					1,656
February Directors Options Issuance
Options to purchase shares issued to Directors					600,000
Options exercise price for share			$ 2.20		$ 2.20
April Directors Options Issuance
Options to purchase shares issued to Directors					350,000
Options to purchase shares issued to Directors, per director					50,000
Additional Options to purchase shares issued to Directors					75,000
Additional Options to purchase shares issued to Directors, per director					25,000
Options exercise price for share			$ 2.55		$ 2.55
Options to purchase common stock issued to Dr. Bernick					150,000
June Directors Options Issuance
Options to purchase shares issued to Directors					250,000
Options exercise price for share			$ 2.80		$ 2.80
Options vesting over a four-year period			5,500		5,500
Options vesting over a two-year period			70,000		70,000
Options vesting over a one-year period			150,000		150,000
Options vesting monthly			75,000		75,000
Options vesting immediately			50,000		50,000
September Options Issuance
Options to Employees					3,914,750
Options to employees exercise price					$ 3.40
Employee options vesting over four years			7,500		7,500
Employee options vesting over two years			115,000		115,000
Employee options vesting over twelve months			2,500		2,500
Lower Range
Warrants exercise price			$ 0.24		$ 0.24
Option Exercise Price			$ 0.10		$ 0.10
Upper Range
Warrants exercise price			$ 3.00		$ 3.00
Option Exercise Price			$ 3.40		$ 3.40
February 24 Debt Issuance
Warrants Issued - Note Modification					5,685,300
Warrants Issued - new Funding					3,314,700
Exercise Price per share of warrants issued					$ 0.38
Fair Value Modification Warrants Issued February 2012					10,505,247
FV Warrants Issued - new Funding					6,124,873
FV Warrants - Assumptions in Black-Scholes Model					Term of 5 years; volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%
FV Warrants - treated as Debt Discount					859,647
Interest Expense					859,647
June 19 Debt Issuance
Warrants Issued - new Funding					7,000,000
Warrants Issued - new funding tranche 1					6,000,000
Warrants Issued - new funding tranche 1 exercise price					$ 2.00
Warrants Issued - new funding tranche 2					1,000,000
Warrants Issued - new funding tranche 2 exercise price					3.00
FV Warrants Issued - new Funding					9,424,982
FV Warrants - Assumptions in Black-Scholes Model					Term of 5 years; volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%
FV Warrants - treated as Debt Discount					1,649,890
Debt discount on notes payable			1,350,162		1,350,162
Amortization of debt discount			$ 247,482		$ 299,728

RELATED PARTIES (Details Narrative) (USD $)	9 Months Ended
RELATED PARTIES (Details Narrative) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Related Parties Details Narrative
Related Party Sales	$ 1,440	$ 11,505
Related Party Receivable	0		0
Related Party Purchases	96,250	0
Related Party Payables	$ 96,250		$ 0
Warrants Assigned	100,000

BUSINESS CONCENTRATIONS (Details Narrative)	3 Months Ended
BUSINESS CONCENTRATIONS (Details Narrative)	Jun. 30, 2012	Sep. 30, 2011
Business Concentrations Details Narrative
Purchase Concentration	65.00%	97.00%

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Commitments And Contingencies Details Narrative
Non-cancelable operating lease term	45
Monthly Base rent of leases	$ 5,443	$ 5,443
Share of monthly operating expenses	3,500	3,500
Rental Expense	84,114	77,570
Future minimum lease payments	$ 84,168

DEPOSITS HELD BY VENDORS (Details Narrative) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
DEPOSITS HELD BY VENDORS (Details Narrative) (USD $)	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2011
Deposits Held By Vendors Details Narrative
Payments for Research and Development of New Products		$ 1,650,000	$ 245,000
Deposits charged to expense	950,000	1,825,000
Remaining balance of deposits	0	0
Estimated additional charge to be incurred in 2012	500,000	500,000
Downpayments for Inventory Purchases		634,000	55,000
Deposits applied to inventory purchases	259,000	420,000
Remaining balance of deposits	269,000	269,000
Downpayments for Inventory Purchase 2		63,000
Outstanding Accounts Payable to Vendor	$ 63,000	$ 63,000

SUBSEQUENT EVENTS (Details Narrative) (USD $)	9 Months Ended
SUBSEQUENT EVENTS (Details Narrative) (USD $)	Sep. 30, 2012
Private Placement
Subsequent event date	Oct. 02, 2012
Subsequent event description	On September 26, 2012, the Company entered into a Securities Purchase Agreement with multiple investors relating to the issuance and sale of the Company's Common Stock in a private placement. The Purchase Agreement was closed on October 2, 2012.
Common stock issued in private placement	3,953,489
Price per share of common stock issued in private placement	$ 2.15
Aggregate purchase price of common stock sold in private placement	$ 8,500,001
Cash fees paid to private placement agent	552,500
Legal fees paid for investors in private placement	27,000
Net proceeds of private placement	$ 7,920,501
Registration statement clause of private placement	As part of the Purchase Agreement, the Company agreed to file a registration statement covering the resale of the Shares no later than 45 days from the Closing Date. The Company shall use its best efforts to effect the registration (including a declaration of effectiveness of the Registration Statement by the SEC) no later than 90 days from the Closing Date (120 days if reviewed by SEC). If the Registration Statement does not become effective on or before the Effectiveness Date, the Company has agreed, among other things, to pay to the Investors 1.5% of each Investors aggregate purchase price of the Shares for each 30-day period that the Registration Statement is not effective, up to a maximum of 10% of such aggregate purchase price.
New Products
Subsequent event date	Nov. 06, 2012
Subsequent event description	The Company plans the release of the following new products in its BocaGreen generic prescription line: BocaGreenMD Prena1 Plus BocaGreenMD Prena1 BocaGreenMD Prena1 Chew
Employment Agreements
Subsequent event date	Nov. 08, 2012
Subsequent event description	On November 8, 2012, the Companys Compensation Committee recommended that the Board of Directors approve employment agreements with the Company&#8217;s executive officers, namely: Chief Executive Officer (Robert G. Finizio), President (John C.K. Milligan, IV) and Chief Financial Officer (Daniel A. Cartwright).
Compensation agreement for Robert Finzio	Compensation for services rendered by Robert G. Finizio as Chief Executive Officer calls for: (i) a time-based ten-year stock option on the employment date to purchase 900,000 shares of the Company's Common Stock with the exercise price equal to the closing price of the Company's Common Stock on November 30, 2012 vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a performance-based ten-year stock option in an amount to be determined, (iii) a base salary of not less than $355,100 per year and (iv) an annual short-term incentive compensation bonus of up to 35% of the base salary.
Compensation agreement for John CK Milligan, IV	Compensation for services rendered by John C.K. Milligan, IV as President calls for: (i) a Time-Based Option on th e employment date to purchase 800,000 shares of the Company's Common Stock with the exercise price equal to the closing price of the Company's Common Stock on November 30, 2012 vesting annually over three years on the anniversary of the employment date, (ii) the right to receive Performance-Based Option in an amount to be determined, (iii) a base salary of not less than $288,100 per year and (iv) an annual short-term incentive compensation bonus of up to 30% of the base salary.
Compensation agreement for Daniel A. Cartwright	Compensation for services rendered by Daniel A. Cartwright as Chief Financial Officer calls for: (i) a Time-Based Option on the employment date to purchase 700,000 shares of the Company's Common Stock with the exercise price equal to the closing price of the Company's Common Stock on November 30, 2012 vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a Performance-Based Option in an amount to be determined, (iii) a base salary of not less than $257,100 per year and (iv) an annual short-term incentive compensation bonus of up to 30% of the base salary.